Session 8 - 12th CROI

Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

Session 8 Oral Abstracts
Diagnosis and Treatment of HIV Infection in Developing Countries
Wednesday, 10 am - 12:30 pm
Ballroom A

Moderators:

James Hakim
Univ of Zimbabwe, Harare

10:00 am 18	Routine HIV Counseling and Testing: Acceptability, Prevalence and HIV Risk Behavior Rhoda Wanyenze*¹, C Liechty², K Ragland², V Masembe³, H Mayanja-Kizza³, D Bangsberg², and M Kamya³ ¹Makerere Univ Inst of Publ Hlth, Kampala, Uganda; ²Univ of California, San Francisco, USA; and ³Makerere Univ, Kampala, Uganda
10:15 am 19	Pregnancy and the Risk of Incident HIV in Rakai, Uganda, a Cause for Concern Ronald Gray*¹, X Li¹, D Serwadda², G Kigozi³, F Wabwire Wabwire-Mangen², H Brahmbhatt¹, M Wawer⁴, and Rakai Health Sciences Program ¹Johns Hopkins Univ, Baltimore, MD, USA; ²Makerere Univ, Kampala, Uganda; ³Rakai Hlth Sci Program, Entebbe, Uganda; and ⁴Columbia Univ, New York, NY, USA
10:30 am 20	Real-time Detection of Patients with Acute HIV Infection in Africa Susan Fiscus*¹, C Pilcher¹, W Miller¹, I Hoffman^1,2, M Price¹, D Chilongozi², C Mapanje², R Krysiak^1,2, M Hosseinipour², S Galvin^1,2, S Gama², F Martinson², and M Cohen¹ ¹Univ of North Carolina at Chapel Hill, USA and ²Univ of North Carolina Project, Lilongwe, Malawi
10:45 am 21	Toxicities from Nevirapine in HIV-infected Males and Females, Including Pregnant Females with Various CD4 Cell Counts N Phanuphak, T Apornpong, S Intarasuk, S Teeratakulpisarn, and Praphan Phanuphak* Thai Red Cross AIDS Res Ctr, Bangkok
11:00 am 22	Short-term Virologic Response to a Triple Nucleoside/Nucleotide Analogue Regimen in Adults with HIV Infection in Africa within the DART Trial Cissy Kityo Mutuluuza*¹, S Walker², P Kaleebu³, V Robertson⁴, R Enzama¹, A Burke², D Yirrell³, A Reid⁴, P Munderi³, D Gibb², C Gilks⁵, P Mugyenyi¹, H Grosskurth³, J Hakim⁴, D Pillay⁶, and the DART Trial ¹Joint Clin Res Ctr, Kampala, Uganda; ²Med Res Council Clin Trials Unit, London, UK; ³Med Res Council/Uganda Virus Res Inst Prgm on AIDS, Entebbe, Uganda; ⁴Univ of Zimbabwe, Harare; ⁵Imperial Coll, London, UK; and ⁶Univ Coll, London, UK
11:15 am 23	Response to Highly Active Retroviral Therapy in Low- and High-income Countries: Analysis of Clinical Databases from 4 Continents Francois Dabis*¹, M Schechter², M Egger³, and ART-LINC/ART-CC STUDY GROUPS ¹Univ Victor Segalen, Bordeaux, France; ²Federal Univ of Rio de Janeiro, Brazil; and ³Univ of Bern, Switzerland
11:30 am 24	Severe Anemia and Associated Risk Factors following Initiation of ZDV-containing Regimens in Adults with HIV Infection in Africa within the DART Trial Francis Ssali*¹, P Munderi², A Reid³, S Walker⁴, W Stohr⁴, C Gilks⁵, and the DART Trial ¹Joint Clin Res Ctr, Kampala, Uganda; ²Med Res Council/Uganda Virus Res Inst Prgm on AIDS, Entebbe, Uganda; ³Univ of Zimbabwe, Harare; ⁴Med Res Council Clin Trials Unit, London, UK; and ⁵Imperial Coll, London, UK
11:45 am 25	Adherence to Antiretroviral Therapy Assessed by Pharrmacy Claims and Survival in HIV-infected South Africans Jean Nachega*^1,3, M Hislop², M Lo¹, S Omer¹, D Dowdy¹, L Regensberg², R Chaisson¹, and G Maartens³ ¹Johns Hopkins Univ, Baltimore, MD, USA; ²Aids for AIDS, Cape Town, South Africa; and ³Univ of Cape Town, South Africa
12:00 pm 26	Lack of Health Insurance is Associated with Lower Response to Highly-Active Antiretroviral Therapy in Treatment Naive Patients at a Large Private Clinic in Botswana Gregory Bisson*¹, J Strom², R Gross¹, X Wang¹, T Gaolathe³, N Ndwapi³, H Friedman¹, I Frank¹, and D Dickinson⁴ ¹Univ of Pennsylvania, Philadelphia, USA; ²Yale Univ, New Haven, CT, USA; ³Republic of Botswana Ministry of Hlth; and ⁴Independence Surgery, Gaborone, Botswana
12:15 pm 27LB	Declines in HIV Prevalence in Uganda: Not as Simple as ABC Maria J Wawer*¹, R Gray², D Serwadda³, Z Namukwaya⁴, F Makumbi⁴, N Sewankambo⁵, X Li⁶, T Lutalo⁷, F Nalugoda⁸, and T Quinn⁹ ¹Columbia Univ Mailman Sch of Publ Hlth, New York, NY, USA; ²Johns Hopkins Bloomberg Sch of Public Health, Baltimore, MD, USA; ³Makerere Univ Inst of Publ Hlth, Kampala, Uganda; ⁴Rakai Health Sciences Program, Kalisizo, Rakai, Uganda; ⁵Makerere Univ, Kampala, Uganda; ⁶Johns Hopkins Bloomber Sch of Public Health, Baltimore, MD, USA; ⁷Uganda Virus research Institute, Entebbe, Uganda; ⁸Rakai Health Sciences Program, Rakai, Uganda.; and ⁹NIAID, Baltimore MD, USA